Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

Clinicaltrials.gov ID: NCT06500741
db-list-check Status RECRUITING
b-loader Phase
b-people Age ≥ 18 Years
b-bullseye-arrow Enrollments 342

Conditions

Prostate Cancer

Summary

The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).

Detailed Description

The study will collect data from eligible patients (six total) and physicians (six total) from one-on-one qualitative interviews and eligible patients from online surveys. Approximately 330 patients with PC will be recruited to complete the online DCE survey.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Central Contacts

Study Director

  • Medical Director

Eligibility Criteria

Inclusion Criteria:

Physician inclusion criteria

* The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
* The physician has cared for at least ten nmHSPC patients in the past year.
* The physician has experience prescribing NHT and ADT. Patient inclusion criteria
* The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.

Exclusion Criteria:

Physician exclusion criteria

* None Patient exclusion criteria
* The patient is castration resistant.
* The patient has metastatic PC.

Study Plan

Participants

Participants will include urologists or oncologists for the physician interviews and prostate cancer patients for the patient interviews and surveys.

  • OTHER:

    No Intervention

    Description:

    No investigational drug will be administered to participants in this study.

Outcome Measures

Primary Outcome Measures

Patients' Preference weights for different treatment attributes

Time Frame: Up to 1 day

Patients' Overall Preference for a specific treatment profile (NHT +/- ADT or ADT monotherapy)

Time Frame: Up to 1 day

Timeline

  • Last Updated
    February 14, 2025
  • Start Date
    July 15, 2024
  • Today
    May 10, 2025
  • Completion Date ( Estimated )
    February 28, 2025

Similar Trials

light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people All Ages